ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $494,794 | -0.5% | 5,284 | -5.1% | 0.01% | +14.3% |
| Q2 2023 | $497,123 | -19.9% | 5,570 | -3.7% | 0.01% | -30.0% |
| Q1 2023 | $620,482 | -13.7% | 5,787 | -1.7% | 0.01% | -16.7% |
| Q4 2022 | $719,346 | -6.8% | 5,890 | -21.2% | 0.01% | -14.3% |
| Q3 2022 | $772,000 | +7.1% | 7,476 | -3.6% | 0.01% | +16.7% |
| Q2 2022 | $721,000 | -45.9% | 7,757 | -31.7% | 0.01% | -36.8% |
| Q1 2022 | $1,333,000 | -17.9% | 11,359 | -5.9% | 0.02% | -13.6% |
| Q4 2021 | $1,624,000 | -22.8% | 12,074 | -8.5% | 0.02% | -26.7% |
| Q3 2021 | $2,103,000 | +55.5% | 13,195 | +28.4% | 0.03% | +57.9% |
| Q2 2021 | $1,352,000 | +34.1% | 10,277 | +31.4% | 0.02% | +18.8% |
| Q1 2021 | $1,008,000 | +34.8% | 7,823 | +74.5% | 0.02% | +33.3% |
| Q4 2020 | $748,000 | +106.1% | 4,484 | +90.7% | 0.01% | +71.4% |
| Q3 2020 | $363,000 | +81.5% | 2,351 | +73.5% | 0.01% | +75.0% |
| Q2 2020 | $200,000 | +308.2% | 1,355 | +210.1% | 0.00% | +300.0% |
| Q1 2020 | $49,000 | – | 437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |